Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients

Documenti analoghi

• Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients
  di: Trivedi, Sumita, et al.
  Pubblicazione: (2016)
• Immune biomarkers of anti-EGFR monoclonal antibody therapy
  di: Trivedi, S., et al.
  Pubblicazione: (2015)
• PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
  di: Concha-Benavente, Fernando, et al.
  Pubblicazione: (2015)
• Identification of the cell-intrinsic and extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer
  di: Concha-Benavente, Fernando, et al.
  Pubblicazione: (2015)
• STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
  di: Srivastava, Raghvendra M, et al.
  Pubblicazione: (2013)